title: Complications in patients after intravitreal injection of bevacizumab.
abstract: OBJECTIVE
  To report complications in patients after intravitreal injection of bevacizumab to treat ocular diseases associated with vascular endothelial growth factor.
  
  
  METHODS
  We retrospectively reviewed the systemic and ocular complications that developed within 2 months of each intravitreal injection of bevacizumab in 707 patients (1300 injections) with intraocular neovascularization or macular oedema.
  
  
  RESULTS
  Nine ocular (1.27%) and eight systemic (1.13%) complications occurred in 707 patients. The ocular complications included corneal abrasion (n = 2), chemosis (n = 2), lens injury (n = 1), ocular inflammation (n = 2), retinal pigment epithelial tear (n = 1) and acute vision loss (n = 1). The systemic complications included cerebral infarction (n = 1), elevation of systolic blood pressure (n = 2), facial skin redness (n = 1), itchy diffuse rash (n = 1) and menstrual irregularities (n = 3).
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab may cause systemic or ocular complications. Caution is advised when considering intravitreal injection of this drug.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Suita, Japan.
authors.forename: Chiharu
authors.initials: C
authors.lastname: Shima
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Fumi
authors.initials: F
authors.lastname: Gomi
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kamei
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ikuno
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oshima
authors.forename: Miki
authors.initials: M
authors.lastname: Sawa
authors.forename: Motokazu
authors.initials: M
authors.lastname: Tsujikawa
authors.forename: Shunji
authors.initials: S
authors.lastname: Kusaka
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002544:Cerebral Infarction / Q000139:chemically induced*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D003316:Corneal Diseases / Q000139:chemically induced; D004890:Erythema / Q000139:chemically induced; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007249:Inflammation / Q000139:chemically induced; D007267:Injections; D007905:Lens Diseases / Q000139:chemically induced; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008599:Menstruation Disturbances / Q000139:chemically induced; D008875:Middle Aged; D012189:Retrospective Studies; D015354:Vision, Low / Q000139:chemically induced*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab